Abstract:BACKGROUND:In addition to directly lysing tumors, oncolytic viruses also induce antitumor immunity by recruiting and activating immune cells in the local tumor microenvironment. However, the activation of the immune cells induced by oncolytic viruses is always accompanied by high-level expression of immune checkpoints in these cells, which may reduce the efficacy of the oncolytic viruses. The aim of this study is to arm the oncolytic vaccinia virus (VV) with immune checkpoint blockade to enhance its antitumor efficacy.METHODS:Through homologous recombination with the parental VV, an engineered VV-scFv-TIGIT was produced, which encodes a single-chain variable fragment (scFv) targeting T-cell immunoglobulin and ITIM domain (TIGIT). The antitumor efficacy of the VV-scFv-TIGIT was explored in several subcutaneous and ascites tumor models. The antitumor efficacy of VV-scFv-TIGIT combined with programmed cell death 1 (PD-1) or lymphocyte-activation gene 3 (LAG-3) blockade was also investigated.RESULTS:The VV-scFv-TIGIT effectively replicated in tumor cells and lysed them, and prompt the infected tumor cells to secret the functional scFv-TIGIT. Compared with control VV, intratumoral injection of VV-scFv-TIGIT in several mouse subcutaneous tumor models showed superior antitumor efficacy, accompanied by more T cell infiltration and a higher degree of CD8+ T cells activation. Intraperitoneal injection of VV-scFv-TIGIT in a mouse model of malignant ascites also significantly improved T cell infiltration and CD8+ T cell activation, resulting in more than 90% of the tumor-bearing mice being cured. Furthermore, the antitumor immune response induced by VV-scFv-TIGIT was dependent on CD8+ T cells which mediated a long-term immunological memory and a systemic antitumor immunity against the same tumor. Finally, the additional combination of PD-1 or LAG-3 blockade further enhanced the antitumor efficacy of VV-scFv-TIGIT, increasing the complete response rate of tumor-bearing mice.CONCLUSIONS:Oncolytic virotherapy using engineered VV-scFv-TIGIT was an effective strategy for cancer immunotherapy. Administration of VV-scFv-TIGIT caused a profound reshaping of the suppressive tumor microenvironment from 'cold' to 'hot' status. VV-scFv-TIGIT also synergized with PD-1 or LAG-3 blockade to achieve a complete response to tumors with poor response to VV or immune checkpoint blockade monotherapy.

ImmunizationAntitumor Efficacy of Lentivector Tumor-Infiltrating T Cells and Enhances the Rescues the Effector Function of Blockade of Programmed Death-1 Pathway

Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

Gold Nanocage-Based Photothermal Ablation Facilitates in Situ Vaccination for Melanoma Therapy.

Immunization with Lentivector Expressing HBV Ag Markedly Improves the Tumor Microenvironment and Result in Regression of Established Tumors (131.44)

Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.

Lentivector Prime and Vaccinia Virus Vector Boost Generate High-Quality Cd8 Memory T Cells and Prevent Autochthonous Mouse Melanoma

Immunoglobulin Fc Fragment Tagging Allows Strong Activation of Endogenous CD4 T Cells to Reshape the Tumor Milieu and Enhance the Antitumor Effect of Lentivector Immunization

Lymph Node and Tumor-Associated PD-L1+ Macrophages Antagonize Dendritic Cell Vaccines by Suppressing CD8+ T Cells

In Vitro-Activated Tumor-Bearing Host T Cells and the Effectiveness of Tumor Vaccine Immunotherapy

Tumor‐Associated Myeloid Cells Selective Delivery of a Therapeutic Tumor Nano‐Vaccine for Overcoming Immune Barriers for Effective and Long‐Term Cancer Immunotherapy

Activation of Endogenous CD4 T Cells Stimulates Favorable Immunologic Changes in the Tumor Milieu and Enhances the Antitumor Effect of Lentivector Immunization (48.15)

In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2

Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l -Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

Cellular Vesicles Expressing PD-1-blocking Scfv Reinvigorate T Cell Immunity Against Cancer

Uplifting Antitumor Immunotherapy with Lymph-Node-Targeted and Ratio-Controlled Codelivery of Tumor Cell Lysate and Adjuvant

Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models

An Engineered Oncolytic Vaccinia Virus Encoding a Single-Chain Variable Fragment Against TIGIT Induces Effective Antitumor Immunity and Synergizes with PD-1 or LAG-3 Blockade.

A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model

Intratumoral Delivery Of A Pd-1-Blocking Scfv Encoded In Oncolytic Hsv-1 Promotes Antitumor Immunity And Synergizes With Tigit Blockade

Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy